OncoLize is preparing first clinical trials to treat pancreatic tumors. Based on solid Proof-of-Concept data and its proprietary OCL platform the company will raise €8.5 Million in two steps. This will start trials in the USA and EU. The round also establishes the pipeline of the same drugs for multiple tumor indications, next to scaling-up to early commercial scale.
Mike de Leeuw was invited to write an expert column in a special feature of ‘Het Financieel Dagblad’ covering a.o. oncology development in the Netherlands. You can read the column here.